Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia

Chronic/refractory immune thrombocytopenia (ITP) is a rare and pathophysiologically heterogeneous disorder with variable responsiveness to available treatments. Sutimlimab, a first-in-class humanized monoclonal anti-C1s IgG4 antibody, selectively inhibits the classical pathway. This phase 1 study (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Broome, Catherine M., Röth, Alexander, Kuter, David J., Scully, Marie, Smith, Roy, Wang, Jennifer, Reuter, Caroline, Hobbs, William, Daak, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Platelets and Thrombopoiesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027504/
https://www.ncbi.nlm.nih.gov/pubmed/35973190
http://dx.doi.org/10.1182/bloodadvances.2021006864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027504/
https://www.ncbi.nlm.nih.gov/pubmed/35973190
http://dx.doi.org/10.1182/bloodadvances.2021006864

Ejemplares similares